

Michael J. Harrington
Sr. Vice President and General Counsel
Lilly Corporate Center
Indianapolis, Indiana 46285 USA

Dear Mr. Harrington,

It has been brought to our attention that Eli Lilly and Company and ICOS Corporation (“Lilly”) have filed multiple Complaints for patent infringement against multiple Abbreviated New Drug Application (“ANDA”) filers. As you are aware, these Complaints are for infringement of U.S. Patent No. 6,943,166 (the “’166 patent”).

We have also been informed that Lilly filed its first Complaint on September 2, 2016. This is one day after the USPTO denied IntelGenx’s request for an Inter Partes Review (“IPR”) of the ‘166 patent.

Finally we note IntelGenx’s press release on November 21, 2016 announcing a binding term sheet between IntelGenx and Lilly for the licensing of the ‘166 patent to IntelGenx.


MonoSol Rx is developing a branded oral soluble film version of tadalafil. This branded product will be detailed by pharmaceutical sales representatives with a focus on urologists. We believe this product offers important choice and differentiation to sufferers. Specifically, our product can be taken with or without water, is packaged on an individual basis for discreteness and portability, and may be easier to swallow for patients suffering from dysphagia.

MonoSol Rx believes the ‘166 patent can be invalidated. We have reviewed the USPTO’s response to IntelGenx and believe a stronger request for opening an IPR can be provided to the USPTO. To this end, we are attaching a draft IPR that we plan on filing with the USPTO on December 5th. We believe this IPR will lead to the invalidation of ‘166 and we are prepared to

MonoSol Rx is prepared to offer Lilly reasonable business terms in order to achieve a mutually agreeable position. We politely request a response from you indicating your level of interest in discussing an amenable solution.

We appreciate your consideration of our proposal and look forward to hearing from you.

Best regards,



Keith Kendall
Chief Executive Officer
kkendall@monosolrx.com
(908) 941-1906